Skip to main content

PIK3CA Biological Pathways Reviews

Videos

Anna Martling, MD, Karolinska Institutet
Videos
01/28/2025
Anna Martling, MD, PhD, discusses study results which found that adjuvant daily aspirin reduced the risk of colorectal cancer recurrence among patients with PI3K alterations.
Anna Martling, MD, PhD, discusses study results which found that adjuvant daily aspirin reduced the risk of colorectal cancer recurrence among patients with PI3K alterations.
Anna Martling, MD, PhD,...
01/28/2025
Oncology
Seth Wander, MD, PhD; Kelly McCann, MD, PhD; Janice Lu, MD, PhD; Megan Kruse, MD
Videos
01/03/2025
Seth Wander, MD; Kelly McCann, MD, PhD; Janice Lu, MD, PhD; Megan Kruse, MD
In this video, a panel of experts discuss PIK3CA-mutant metastatic breast cancer, including the newest data on inavolisib from the INAVO120 trial.
In this video, a panel of experts discuss PIK3CA-mutant metastatic breast cancer, including the newest data on inavolisib from the INAVO120 trial.
In this video, a panel of...
01/03/2025
Oncology
Seth Wander, MD, PhD; Kelly McCann, MD, PhD; Janice Lu, MD, PhD; Megan Kruse, MD
Videos
01/03/2025
Seth Wander, MD; Kelly McCann, MD, PhD; Janice Lu, MD, PhD; Megan Kruse, MD
In this video, a panel of experts discuss PIK3CA-mutant metastatic breast cancer, including the agents targeting PI3K signaling.
In this video, a panel of experts discuss PIK3CA-mutant metastatic breast cancer, including the agents targeting PI3K signaling.
In this video, a panel of...
01/03/2025
Oncology
Seth Wander, MD, PhD; Kelly McCann, MD, PhD; Janice Lu, MD, PhD; Megan Kruse, MD
Videos
01/02/2025
Seth Wander, MD; Kelly McCann, MD, PhD; Janice Lu, MD, PhD; Megan Kruse, MD
In this video, a panel of experts discuss PIK3CA-mutant metastatic breast cancer, including an overview of the PI3 kinase pathway in cancer.
In this video, a panel of experts discuss PIK3CA-mutant metastatic breast cancer, including an overview of the PI3 kinase pathway in cancer.
In this video, a panel of...
01/02/2025
Oncology
Alberto Montero, MD, UH Seidman Cancer Center
Videos
10/17/2024
Alberto Montero, MD
Alberto Montero, MD, discusses phase 1/2 study results which demonstrated that STX-478 shows promise in patients with heavily pre-treated PI3Kα-mutated solid tumors.
Alberto Montero, MD, discusses phase 1/2 study results which demonstrated that STX-478 shows promise in patients with heavily pre-treated PI3Kα-mutated solid tumors.
Alberto Montero, MD, discusses...
10/17/2024
Oncology
Demetria Smith-Graziani, MD, MPH, Winship Cancer Institute
Videos
09/24/2024
Demetria J. Smith-Graziani, MD, MPH
Demetria Smith-Graziani, MD, MPH, describes the currently enrolling and ongoing INAVO121 trial, evaluating inavolisib vs alpelisib, both in combination with fulvestrant, for patients with PIK3CA-mutated, hormone receptor-positive,...
Demetria Smith-Graziani, MD, MPH, describes the currently enrolling and ongoing INAVO121 trial, evaluating inavolisib vs alpelisib, both in combination with fulvestrant, for patients with PIK3CA-mutated, hormone receptor-positive,...
Demetria Smith-Graziani, MD,...
09/24/2024
Oncology
Heather McArthur, MD
Videos
09/16/2024
Heather McArthur, MD, discusses results from the phase 3 CAPItello-290 trial which evaluated capivasertib plus paclitaxel as first-line treatment for patients with metastatic triple-negative breast cancer.
Heather McArthur, MD, discusses results from the phase 3 CAPItello-290 trial which evaluated capivasertib plus paclitaxel as first-line treatment for patients with metastatic triple-negative breast cancer.
Heather McArthur, MD, discusses...
09/16/2024
Oncology
Demetria Smith-Graziani, MD, MPH, Winship Cancer Institute
Videos
09/03/2024
Demetria J. Smith-Graziani, MD, MPH
Demetria Smith-Graziani, MD, MPH, shares insights from the results of the phase 3 INAVO120 study, evaluating the addition of inavolisib to palbociclib and fulvestrant for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced...
Demetria Smith-Graziani, MD, MPH, shares insights from the results of the phase 3 INAVO120 study, evaluating the addition of inavolisib to palbociclib and fulvestrant for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced...
Demetria Smith-Graziani, MD,...
09/03/2024
Oncology
Ghassan Abou-Alfa, MD
Videos
05/19/2026
Ghassan Abou-Alfa, MD, MBA
Ghassan Abou-Alfa, MD, discusses results from the phase 3 PROOF 301 trial evaluating infigratinib in patients with FGFR2 fusion-positive cholangiocarcinoma.
Ghassan Abou-Alfa, MD, discusses results from the phase 3 PROOF 301 trial evaluating infigratinib in patients with FGFR2 fusion-positive cholangiocarcinoma.
Ghassan Abou-Alfa, MD, discusses...
05/19/2026
Oncology
Lajos Pusztai, MD, DPhil
Videos
05/19/2026
Lajos Pusztai, MD, DPhil
Lajos Pusztai, MD, DPhil, discusses post hoc analysis results from the of the phase 3 DESTINY-Breast11 trial assessing neoadjuvant T-DXd plus paclitaxel, trastuzumab, and pertuzumab in HER2-positive early breast cancer.
Lajos Pusztai, MD, DPhil, discusses post hoc analysis results from the of the phase 3 DESTINY-Breast11 trial assessing neoadjuvant T-DXd plus paclitaxel, trastuzumab, and pertuzumab in HER2-positive early breast cancer.
Lajos Pusztai, MD, DPhil,...
05/19/2026
Oncology
Alison Scram, MD
Videos
05/19/2026
Alison Schram, MD
Alison Schram, MD, discusses results from the phase 2 eNRGy trial which led to the recent FDA approval of zenocutuzumab for patients with NRG1-fusion positive cholangiocarcinoma.
Alison Schram, MD, discusses results from the phase 2 eNRGy trial which led to the recent FDA approval of zenocutuzumab for patients with NRG1-fusion positive cholangiocarcinoma.
Alison Schram, MD, discusses...
05/19/2026
Oncology
Rana McKay, MD
Videos
05/19/2026
Rana McKay, MD
Rana McKay, MD, discusses results from the ARASEC trial evaluating darolutamide plus ADT in metastatic hormone-sensitive prostate cancer.
Rana McKay, MD, discusses results from the ARASEC trial evaluating darolutamide plus ADT in metastatic hormone-sensitive prostate cancer.
Rana McKay, MD, discusses...
05/19/2026
Oncology
Videos
05/15/2026
Oncology Learning Network APP Institute
Videos
05/15/2026
Oncology Learning Network APP Institute
Videos
05/15/2026
Oncology Learning Network APP Institute
Videos
05/15/2026
Oncology Learning Network APP Institute
Ismail Gögenur, MD, DMSc
Videos
05/15/2026
Ismail Gögenur, MD, DMSc, discusses results from the RESET-C trial evaluating a single cycle of neoadjuvant pembrolizumab in patients with mismatch repair–deficient colon cancer.
Ismail Gögenur, MD, DMSc, discusses results from the RESET-C trial evaluating a single cycle of neoadjuvant pembrolizumab in patients with mismatch repair–deficient colon cancer.
Ismail Gögenur, MD, DMSc,...
05/15/2026
Oncology
Sai-Wei Huang, MD
Videos
05/13/2026
Sai-Wei Huang, MD
Sai-Wei Huang, MD, discusses findings from a study evaluating metabolic biomarkers in patients with nasopharyngeal carcinoma using RNA sequencing.
Sai-Wei Huang, MD, discusses findings from a study evaluating metabolic biomarkers in patients with nasopharyngeal carcinoma using RNA sequencing.
Sai-Wei Huang, MD, discusses...
05/13/2026
Oncology
OLN

PIK3CA

ALIASES

Phosphatidylinositol 3-kinase catalytic subunit

References

PIK3CA (phosphatidylinositol 3-kinase catalytic subunit) is an oncogene that encodes one piece (a subunit) of an enzyme called phosphatidylinositol 3-kinase (PI3-Kinase).1 PIK3CA plays a role in the control of cell growth, cell survival, and cell migration. Mutations in the PIK3CA gene can lead to uncontrolled cell growth and contribute to the proliferation and progression of cancer.2 

The PI3-Kinase pathway is one of many signaling pathways that are important for cell growth, transformation, adhesion, apoptosis, survival and invasion.3 PI3-Kinases are heterodimeric lipid kinases composed of catalytic and adaptor/regulatory subunits encoded by separate genes and alternative splicing. In the case of oncogenes, including PIK3CA, genetic changes such as a mutation can result in a cellular state whereby the PIK3CA gene product is constantly activated. Ultimately, this contributes toward uncontrolled cellular growth and other features that are the hallmarks of cancer.1

Gene amplifications, deletions and more recently, somatic missense mutations in the PIK3CA gene have been reported in many human cancer types including cancers of the colon, breast, brain, liver, stomach and lung. These somatic missense mutations were proposed to increase the kinase activity of PIK3CA contributing to cellular transformation.3

PIK3CA mutations are found in 20% to 25% of colon cancers and 10% of rectal cancers. In addition to colorectal cancer, PIK3CA oncogene mutations are involved in several human cancers including breast cancer, ovarian cancer, and non-small cell lung cancer (NSCLC).2

Understanding the Role of PIK3CA

News

Conference Coverage
12/03/2024
Allison Casey
According to a phase 1/2 study, the PI3K-alpha inhibitor, STX-478, showed promise among patients with PIK3CA-mutant solid tumors and/or HR-positive, HER2-negative breast cancer.
According to a phase 1/2 study, the PI3K-alpha inhibitor, STX-478, showed promise among patients with PIK3CA-mutant solid tumors and/or HR-positive, HER2-negative breast cancer.
According to a phase 1/2 study,...
12/03/2024
Oncology
Conference Coverage
12/03/2024
Allison Casey
In the PIKASSO-01 trial, LOXO-783 demonstrated a proof of mutant selectivity among patients with PIK3CA H1047R-mutant solid tumors. However, the rate of diarrhea prevented the determination of an optimal preclinical dose.
In the PIKASSO-01 trial, LOXO-783 demonstrated a proof of mutant selectivity among patients with PIK3CA H1047R-mutant solid tumors. However, the rate of diarrhea prevented the determination of an optimal preclinical dose.
In the PIKASSO-01 trial,...
12/03/2024
Oncology
News
11/05/2024
Allison Casey
According to a single-center cohort study, there was a substantial overall survival disparity, with differing frequencies of driver gene variations, by race and ethnicity.
According to a single-center cohort study, there was a substantial overall survival disparity, with differing frequencies of driver gene variations, by race and ethnicity.
According to a single-center...
11/05/2024
Oncology
News
10/31/2024
A multi-gene target panel NGS assay was found to be feasible and accurate when detecting mutations in patients with advanced HR-positive, HER2-negative breast cancer.
A multi-gene target panel NGS assay was found to be feasible and accurate when detecting mutations in patients with advanced HR-positive, HER2-negative breast cancer.
A multi-gene target panel NGS...
10/31/2024
Oncology
FDA Approval
10/10/2024
Allison Casey
The FDA has approved inavolisib, with palbociclib and fulvestrant for patients with endocrine-resistant, PIK3CA-mutated HR-positive, HER2-negative locally advanced or metastatic breast cancer.
The FDA has approved inavolisib, with palbociclib and fulvestrant for patients with endocrine-resistant, PIK3CA-mutated HR-positive, HER2-negative locally advanced or metastatic breast cancer.
The FDA has approved inavolisib,...
10/10/2024
Oncology
News
10/02/2024
Allison Casey
The phase 3 SAKK 41/13 trial provides the first prospective data that there is a protective effect with adjuvant advil among patients with resected, PIK3CA-mutant colon cancer.
The phase 3 SAKK 41/13 trial provides the first prospective data that there is a protective effect with adjuvant advil among patients with resected, PIK3CA-mutant colon cancer.
The phase 3 SAKK 41/13 trial...
10/02/2024
Oncology
News
09/24/2024
Allison Casey
The ongoing INAVO121 trial is open for enrollment of patients with hormone receptor-positive, HER2-negative, PIK3CA-mutated locally advanced or metastatic breast cancer who progressed during or after a CDK4/6-inhibitor–based regimen.
The ongoing INAVO121 trial is open for enrollment of patients with hormone receptor-positive, HER2-negative, PIK3CA-mutated locally advanced or metastatic breast cancer who progressed during or after a CDK4/6-inhibitor–based regimen.
The ongoing INAVO121 trial is...
09/24/2024
Oncology
Conference Coverage
12/08/2023
Stephanie Holland
According to primary analysis results from the phase 3 INAVO120 trial, the addition of inavolisib to palbociclib plus fulvestrant significantly improved investigator-assessed progression-free survival in PIK3CA-mutated, hormone...
According to primary analysis results from the phase 3 INAVO120 trial, the addition of inavolisib to palbociclib plus fulvestrant significantly improved investigator-assessed progression-free survival in PIK3CA-mutated, hormone...
According to primary analysis...
12/08/2023
Oncology
News
05/19/2026
Emily Estrada
Results from the phase 3 SKYSCRAPER-02C trial demonstrated that adding tiragolumab to atezolizumab plus chemotherapy did not significantly improve survival in treatment-naïve patients with extensive-stage small cell lung cancer.
Results from the phase 3 SKYSCRAPER-02C trial demonstrated that adding tiragolumab to atezolizumab plus chemotherapy did not significantly improve survival in treatment-naïve patients with extensive-stage small cell lung cancer.
Results from the phase 3...
05/19/2026
Oncology
News
05/19/2026
Emily Estrada
Results from a prospective study suggest that ctDNA dynamics may help stratify recurrence risk in patients with liver-limited metastatic colorectal cancer undergoing liver resection after upfront chemotherapy.
Results from a prospective study suggest that ctDNA dynamics may help stratify recurrence risk in patients with liver-limited metastatic colorectal cancer undergoing liver resection after upfront chemotherapy.
Results from a prospective study...
05/19/2026
Oncology
News
05/19/2026
Stephanie Holland
Updated results from the POTOMAC trial demonstrate that durvalumab plus Bacillus Calmetter-Guerin (BCG) induction and maintenance reduced recurrence-related outcomes in patients with high-risk non-muscle-invasive bladder cancer.
Updated results from the POTOMAC trial demonstrate that durvalumab plus Bacillus Calmetter-Guerin (BCG) induction and maintenance reduced recurrence-related outcomes in patients with high-risk non-muscle-invasive bladder cancer.
Updated results from the POTOMAC...
05/19/2026
Oncology
FDA Approval
05/18/2026
Stephanie Holland
Based on results from the phase 3 DESTINY-Breast11 and DESTINY-Breast05 trials the FDA has approved neoadjuvant and adjuvant trastuzumab deruxtecan for patients with HER2-positive early breast cancer.
Based on results from the phase 3 DESTINY-Breast11 and DESTINY-Breast05 trials the FDA has approved neoadjuvant and adjuvant trastuzumab deruxtecan for patients with HER2-positive early breast cancer.
Based on results from the phase...
05/18/2026
Oncology
FDA Approval
05/15/2026
Emily Estrada
Based on results from the IMvigor011 trial, the FDA has approved adjuvant atezolizumab and atezolizumab plus hyaluronidase for ctDNA-positive patients with muscle-invasive bladder cancer.
Based on results from the IMvigor011 trial, the FDA has approved adjuvant atezolizumab and atezolizumab plus hyaluronidase for ctDNA-positive patients with muscle-invasive bladder cancer.
Based on results from the...
05/15/2026
Oncology
News
05/15/2026
Emily Estrada
Results from the phase 1 BTX-9341-101 trial demonstrated that BTX-9341 shows encouraging efficacy and safety in heavily pretreated patients with HR-positive, HER2-negative advanced or metastatic breast cancer.
Results from the phase 1 BTX-9341-101 trial demonstrated that BTX-9341 shows encouraging efficacy and safety in heavily pretreated patients with HR-positive, HER2-negative advanced or metastatic breast cancer.
Results from the phase 1...
05/15/2026
Oncology
News
05/15/2026
Emily Estrada
A chemotherapy-free, pCR-guided strategy with dual HER2 blockade achieved high response rates and preserved quality of life in patients with HER2-positive early breast cancer.
A chemotherapy-free, pCR-guided strategy with dual HER2 blockade achieved high response rates and preserved quality of life in patients with HER2-positive early breast cancer.
A chemotherapy-free, pCR-guided...
05/15/2026
Oncology
News
05/14/2026
Stephanie Holland
First-line treatment with zongertinib showed sustained efficacy in advanced or metastatic HER2-mutated non-small-cell lung cancer, according to results from the phase 1a/1b Beamion LUNG-1 trial.
First-line treatment with zongertinib showed sustained efficacy in advanced or metastatic HER2-mutated non-small-cell lung cancer, according to results from the phase 1a/1b Beamion LUNG-1 trial.
First-line treatment with...
05/14/2026
Oncology
FDA Alerts
05/13/2026
Emily Estrada
The FDA issued a safety alert regarding tazemetostat, citing an increased risk of hematologic second primary malignancies observed in the ongoing SYMPHONY-1 trial.
The FDA issued a safety alert regarding tazemetostat, citing an increased risk of hematologic second primary malignancies observed in the ongoing SYMPHONY-1 trial.
The FDA issued a safety alert...
05/13/2026
Oncology
FDA Approval
05/13/2026
Emily Estrada
Based on results from the BGB-11417-201 trial, the FDA has approved sonrotoclax for previously treated patients with relapsed/refractory mantle cell lymphoma.
Based on results from the BGB-11417-201 trial, the FDA has approved sonrotoclax for previously treated patients with relapsed/refractory mantle cell lymphoma.
Based on results from the...
05/13/2026
Oncology

Quizzes

Quiz
09/25/2024
Do you know what the progression-free survival was for the inavolisib arm in the INAVO120 trial? Test your knowledge with our quick quiz.
Do you know what the progression-free survival was for the inavolisib arm in the INAVO120 trial? Test your knowledge with our quick quiz.
Do you know what the...
09/25/2024
Oncology
Quiz
09/25/2024
Do you know what percentage of patients with hormone receptor-positive, HER2-negative breast cancer have a PIK3CA mutation? Take our quick quiz to find out!
Do you know what percentage of patients with hormone receptor-positive, HER2-negative breast cancer have a PIK3CA mutation? Take our quick quiz to find out!
Do you know what percentage of...
09/25/2024
Oncology
Quiz
05/01/2026
Which genomic feature predicts poor survival with ruxolitinib plus venetoclax in patients with R/R acute myeloid leukemia?
Which genomic feature predicts poor survival with ruxolitinib plus venetoclax in patients with R/R acute myeloid leukemia?
Which genomic feature predicts...
05/01/2026
Oncology
Quiz
05/01/2026
Results from a translational analysis of patients with high-grade glioma demonstrated that which of the following immune cell population changes distinguished long-term survivors from short-term survivors?
Results from a translational analysis of patients with high-grade glioma demonstrated that which of the following immune cell population changes distinguished long-term survivors from short-term survivors?
Results from a translational...
05/01/2026
Oncology
Quiz
04/02/2026
In patients with extensive-stage small cell lung cancer receiving chemoimmunotherapy, which thoracic radiotherapy strategy was associated with improved survival outcomes?
In patients with extensive-stage small cell lung cancer receiving chemoimmunotherapy, which thoracic radiotherapy strategy was associated with improved survival outcomes?
In patients with extensive-stage...
04/02/2026
Oncology
Quiz
04/01/2026
Emily Estrada
True or False: Results from the STELLAR-303 trial demonstrate that zanzalintinib plus atezolizumab does not significantly improve overall survival compared with regorafenib in patients with relapsed/refractory metastatic colorectal cancer...
True or False: Results from the STELLAR-303 trial demonstrate that zanzalintinib plus atezolizumab does not significantly improve overall survival compared with regorafenib in patients with relapsed/refractory metastatic colorectal cancer...
True or False: Results from the...
04/01/2026
Oncology
Quiz
03/31/2026
Did auceliciclib demonstrate acceptable tolerability and preliminary signs of clinical activity in patients with advanced solid tumors and recurrent/relapsed high-grade glioma?
Did auceliciclib demonstrate acceptable tolerability and preliminary signs of clinical activity in patients with advanced solid tumors and recurrent/relapsed high-grade glioma?
Did auceliciclib demonstrate...
03/31/2026
Oncology
Quiz
03/18/2026
Test your knowledge of the clinical benefit of tucatinib plus trastuzumab therapy in patients with chemotherapy-refractory, HER2-positive, RAS wild-type metastatic colorectal cancer.
Test your knowledge of the clinical benefit of tucatinib plus trastuzumab therapy in patients with chemotherapy-refractory, HER2-positive, RAS wild-type metastatic colorectal cancer.
Test your knowledge of the...
03/18/2026
Oncology
Quiz
03/04/2026
Test your knowledge of how serum LDH and α-HBDH levels following first-line chemoimmunotherapy may influence survival outcomes in extensive-stage small cell lung cancer (ES-SCLC).
Test your knowledge of how serum LDH and α-HBDH levels following first-line chemoimmunotherapy may influence survival outcomes in extensive-stage small cell lung cancer (ES-SCLC).
Test your knowledge of how serum...
03/04/2026
Oncology
Quiz
03/03/2026
Test your knowledge on a multi-omics model for predicting responses to whole-brain radiotherapy among patents with small cell lung cancer.
Test your knowledge on a multi-omics model for predicting responses to whole-brain radiotherapy among patents with small cell lung cancer.
Test your knowledge on a...
03/03/2026
Oncology
Quiz
03/03/2026
Test your knowledge on safusidenib erbumine, a selective mutant IDH1 inhibitor, patients with newly diagnosed, chemotherapy- and radiotherapy-naïve grade 2 IDH1-mutated gliomas.
Test your knowledge on safusidenib erbumine, a selective mutant IDH1 inhibitor, patients with newly diagnosed, chemotherapy- and radiotherapy-naïve grade 2 IDH1-mutated gliomas.
Test your knowledge on...
03/03/2026
Oncology
Quiz
03/02/2026
Test your knowledge on the response rates and survival outcomes of chidamide, azacitidine, cytarabine, aclarubicin, G-CSF (CACAG), and venetoclax therapy for patients with R/R acute myeloid leukemia.
Test your knowledge on the response rates and survival outcomes of chidamide, azacitidine, cytarabine, aclarubicin, G-CSF (CACAG), and venetoclax therapy for patients with R/R acute myeloid leukemia.
Test your knowledge on the...
03/02/2026
Oncology